Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The study addresses the question if the first line therapy of low malignant and mantle cell
lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus
rituximab with regard to progression free survival (PFS).